Certara, a global biosimulation technology-enabled drug development consultancy, is endowing a new three-year, full-time position—the Certara lecturer in precision dosing—at the Manchester Pharmacy School, the University of Manchester, England. This lectureship is intended to advance teaching and research into individual dose optimization modeling, and to demonstrate its application to cancer, pediatric and biologic therapies.

This new lecturer will work closely with the clinical pharmacy, clinical pharmacology and quantitative proteomics research groups at the University of Manchester to raise the profile of precision dosing within the university’s precision medicine initiative. This staff member also will lead post-graduate modeling and simulation programs.

“Our work with global biopharm companies and regulatory agencies demonstrates the advantages of using biosimulation to answer precision dosing questions for specific cohorts such as pediatric or geriatric patients, women who are pregnant or patients with co-morbidities,” said Edmundo Muniz, M.D., Ph.D., Certara CEO.

This new lecturer will become a member of the Systems Pharmacology Group within Manchester Pharmacy School. The postholder will report to the head of the school and be mentored by professor Amin Rostami, Pharm.D., Ph.D., professor of systems pharmacology at the University of Manchester, and Certara’s chief scientific officer.